Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

  • Teva entered into an agreement with JKI Co., Ltd. (“JKI”) established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ('J-Will”), through which JKI will acquire Teva-Takeda
  • The agreement is aligned with Teva's Pivot to Growth strategy to focus its business
  • The expected divestment of Teva-Takeda, Teva's business venture in Japan, which includes generics products and legacy products, will allow Teva to focus on bringing its innovative medicines to the Japanese market

TEL AVIV, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.

Teva recently communicated that it was open to exploring new strategic approaches in Japan, including a possible divestment of its Teva-Takeda business venture, in alignment with its Pivot to Growth strategy. The divestment will allow Teva to focus on its innovative medicines business in Japan.

Teva expects the divestiture to be completed by 1 April, 2025, subject to standard closing conditions, including obtaining required regulatory approvals. All the employees of the business venture in Japan will remain employed, subject to the terms of the agreement.

“This is another step in our Pivot to Growth strategy to focus the business,” said Mark Sabag, Executive Vice President, International Markets Commercial. “Furthermore, we are confident that this agreement with JKI will ensure the continued delivery of high-quality, affordable medicines to patients in Japan.”

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks and uncertainties relating to: our ability to successfully divest our Teva-Takeda business venture in Japan; the terms, timing, structure, benefits and costs of such divestiture and whether such divestiture will be consummated at all; the impact of any divestiture transaction on the remaining businesses of Teva in Japan and our ability to focus on our innovative business in Japan; our ability to satisfy the closing conditions to completing the divestiture of our business venture in Japan, including to obtain the required regulatory approvals; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned 'Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

IR Contacts Chris Stevo+1 (339) 213-3999
  Yael Ashman+972 (3) 914 8262
  Sanjeev Sharma+1 (973) 658 2700 
PR Contacts Kelley Dougherty
Eden Klein
+1 (973) 832-2810
+972 (3) 906 2645

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan


THỦ THUẬT HAY

Biến hoá cho "tai thỏ" của iPhone X với ứng dụng Custom Notch

Mặc dù vậy, nó cũng khiến cho người dùng cảm thấy khó chịu trong quá trình sử dụng, thậm chí là có phần dư thừa trên màn hình thiết bị.

Cách tăng tốc độ download cho smartphone Android

Bạn thường xuyên dùng thiết bị Android của mình để download phim, ứng dụng,...nhưng đôi lúc cảm thấy khó chịu khi tốc độ Internet quá chậm hoặc không ổn định? Tham khảo bài viết sau của chúng tôi để cải thiện và tăng

Xem video Picture-in-Picture với trình duyệt Chrome trên Android 8 Oreo

Một trong những tính năng hay nhất của Android 8 là Picture in Picture (PiP), cho phép bạn xem video dạng cửa sổ thu nhỏ vừa sử dụng một app khác. Hiện chưa có nhiều app hỗ trợ chức năng này, chỉ mới có Chrome, YouTube

12 ứng dụng dành cho Android đang miễn phí và giảm giá

Tiếp tục cập nhật danh sách 'Free App' hằng ngày dành cho smartphone Android, TCN đã tổng hợp thêm khá nhiều ứng dụng và game trả phí đang được miễn phí. Nếu bạn quan tâm hãy nhanh tay tải về trước khi bị tính phí trở

ĐÁNH GIÁ NHANH

So sánh Xiaomi 11T và Xiaomi 11T Pro: Đâu là lựa chọn tốt nhất?

Xiaomi 11T và Xiaomi 11T Pro đã chính thức ra mắt trên toàn cầu với mức giá khá mềm và sở hữu cấu hình vượt trội. Vậy giữa hai thiết bị này nên chọn mua thiết bị nào? Hãy cùng mình đi so sánh Xiaomi 11T và Xiaomi 11T

Đánh giá Loa Bluetooth Tronsmart Element T6 – Gã black panther châu Á

Tronsmart là cái tên còn khá mới lạ bên cạnh những ông lớn như Sony, JBL,.. nhưng không vì thế mà hãng loa đến từ Trung Quốc này sản xuất nhưng sản phẩm giá rẻ với chất lượng làng nhàng như đồng hương khác. Chất lượng

Đánh giá Wiko View XL- Smartphonemàn hình Fullview tỉ lệ 18:9 giá 5 triệu

5 triệu đồng là mức giá mà hầu hệt người dùng sẵn lòng trả, nhưng với Wiko View XL- số tiền bạn bỏ ra thật sự “đáng đồng tiền bát gạo” .